Dactolisib (BEZ235)

For research use only. Not for use in humans.

目录号：S1009 别名： NVP-BEZ235 中文名称：达克利司

CAS No. 915019-65-7

Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。在 3T3^TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Dactolisib可诱导自噬并抑制HIV-1的复制。Phase 2。

规格

价格

库存

购买数量

50mg	RMB 895.88	现货
200mg	RMB 2530.71	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Dactolisib (BEZ235)发表文献416篇：

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 13;149(2):307-21.

PubMed: 22500798 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Sci Rep, 2022, 12(1):241

PubMed: 34997132 ( click the link to review the publication )

Curr Res Pharmacol Drug Discov, 2022, 3:100076

PubMed: 35005610 ( click the link to review the publication )

Nat Commun, 2021, 12(1):7268

PubMed: 34907175 ( click the link to review the publication )

Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-21-1943

PubMed: 34921019 ( click the link to review the publication )

EMBO Mol Med, 2021, e14511

PubMed: 34779136 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Cell Rep, 2021, 35(1):108940

PubMed: 33784499 ( click the link to review the publication )

Cell Rep, 2021, 35(8):109181

PubMed: 34038737 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5736

PubMed: 34086347 ( click the link to review the publication )

Cancers (Basel), 2021, 13(9)2139

PubMed: 33946744 ( click the link to review the publication )

Cancers (Basel), 2021, 13(11)2778

PubMed: 34204960 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):713

PubMed: 34272360 ( click the link to review the publication )
Cell Chem Biol, 2021, S2451-9456(21)00254-3

PubMed: 34111400 ( click the link to review the publication )

Clin Sci (Lond), 2021, CS20210571

PubMed: 34282832 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:621906

PubMed: 34124031 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(20)11260

PubMed: 34681918 ( click the link to review the publication )

Int J Nanomedicine, 2021, 16:2173-2186

PubMed: 33758505 ( click the link to review the publication )

Sci Rep, 2021, 11(1):23302

PubMed: 34857796 ( click the link to review the publication )

Sci Rep, 2021, 11(1):10461

PubMed: 34002003 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00805-X

PubMed: 34303705 ( click the link to review the publication )

Int J Oncol, 2021, 10.3892/ijo.2021.5167

PubMed: 33491755 ( click the link to review the publication )

Neuroscience, 2021, S0306-4522(21)00070-1

PubMed: 33577953 ( click the link to review the publication )

SLAS Technol, 2021, 24726303211008858

PubMed: 33880947 ( click the link to review the publication )

J Burn Care Res, 2021, irz170

PubMed: 34213565 ( click the link to review the publication )

Biol Pharm Bull, 2021, 10.1248/bpb.b21-00531

PubMed: 34602526 ( click the link to review the publication )

Viruses, 2021, 13(6)1062

PubMed: 34205098 ( click the link to review the publication )

Oncotarget, 2021, 12(7):674-685

PubMed: 33868588 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

Nat Microbiol, 2020, 10.1038/s41564-020-0782-1

PubMed: 32895527 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1825

PubMed: 32286280 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 246:120012

PubMed: 32276198 ( click the link to review the publication )

Theranostics, 2020, 16;10(14):6448-6466

PubMed: 32483463 ( click the link to review the publication )

Cell Rep, 2020, 32(12):108171

PubMed: 32966799 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )
Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E3058

PubMed: 33092134 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3689

PubMed: 33316942 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32085396 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )

J Mol Cell Biol, 2020, 12(8):644-653

PubMed: 31065693 ( click the link to review the publication )

Bioinformatics, 2020, btaa858

PubMed: 33067636 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):479-489

PubMed: 31672764 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12888

PubMed: 33338300 ( click the link to review the publication )

J Cancer, 2020, 11(9):2552-2559

PubMed: 32201525 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4488-4497

PubMed: 33415013 ( click the link to review the publication )

Front Cell Neurosci, 2020, 15;14:134

PubMed: 32477073 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9240

PubMed: 33287446 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32708306 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7649

PubMed: 33081092 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):15837

PubMed: 32985581 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):4

PubMed: 31898540 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.3432

PubMed: 32976685 ( click the link to review the publication )
G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(3):2217-2230

PubMed: 32088816 ( click the link to review the publication )

Oncol Lett, 2020, 20(6):326

PubMed: 33123242 ( click the link to review the publication )

J BUON, 2020, 020;25(1):464-471

PubMed: 32277670 ( click the link to review the publication )

Nanoscale Res Lett, 2020, 15(1):63

PubMed: 32219609 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(6):1900-1918

PubMed: 32642299 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

Can J Physiol Pharmacol, 2020, 10.1139/cjpp-2020-0280

PubMed: 32893666 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29926

PubMed: 32654229 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Commun Biol, 2020, 3(1):524

PubMed: 32963283 ( click the link to review the publication )

Biochem Genet, 2020, 10.1007/s10528-020-09982-x

PubMed: 32671511 ( click the link to review the publication )

Elife, 2020, 9:e53367

PubMed: 32513387 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-4245

PubMed: 32605911 ( click the link to review the publication )

Biomaterials, 2020, 230:119618

PubMed: 31757530 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 43(2):223-235

PubMed: 31776938 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11487

PubMed: 32661241 ( click the link to review the publication )

Cell Rep, 2020, 32(3):107933

PubMed: 32697996 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Clin Transl Med, 2020, 9(1):22

PubMed: 32112175 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )
Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Cell Death Differ, 2019, 26(3):548-564

PubMed: 30050055 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )
Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2019, 316(1):H61-H69

PubMed: 30359076 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Am J Transl Res, 2019, 11(10):6534-6543

PubMed: 31737204 ( click the link to review the publication )

Am J Transl Res, 2019, 11(12):7255-7271

PubMed: 31934276 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Oncol Rep, 2019, 10.3892/or.2019.7265

PubMed: 31524277 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

PLoS One, 2019, 14(5):e0216603

PubMed: 31100067 ( click the link to review the publication )

Reprod Sci, 2019, 1933719119828067

PubMed: 30791863 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Exp Ther Med, 2019, 18(3):2278-2284

PubMed: 31410178 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )
Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

ACS Pharmacol Transl Sci, 2019,

PubMed: 32259061 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2018,

PubMed: 30224486 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563275 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Virulence, 2018, 9(1):83-98

PubMed: 28475412 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )
Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5808-5820

PubMed: 29475942 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )
Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10483-10496

PubMed: 29535821 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Sci Signal, 2017, 10(507)eaam7550

PubMed: 29184034 ( click the link to review the publication )

J Med Chem, 2017,

PubMed: 28471660 ( click the link to review the publication )

Cancers (Basel), 2017, 9(9)E125

PubMed: 28926938 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):102-115

PubMed: 27980105 ( click the link to review the publication )

Mol Oncol, 2017, 11(9):1130-1142

PubMed: 28544747 ( click the link to review the publication )

Mol Oncol, 2017, 11(5):470-490

PubMed: 28173629 ( click the link to review the publication )
J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10612

PubMed: 28878291 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12406

PubMed: 28963527 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

Cell Cycle, 2017, 16(24):2386-2395

PubMed: 28980866 ( click the link to review the publication )

World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Cell Cycle, 2017, 16(21):2146-2155

PubMed: 28910567 ( click the link to review the publication )

Oncotarget, 2017, 8(50):88043-88058

PubMed: 29152140 ( click the link to review the publication )

Oncotarget, 2017, 8(30):49380-49394

PubMed: 28537902 ( click the link to review the publication )

Oncotarget, 2017, 8(63):106486-106498

PubMed: 29290965 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )
Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7265-7275

PubMed: 27980219 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

Oncogene, 2016, 35(38):5010-20

PubMed: 26973247 ( click the link to review the publication )

Cancer Lett, 2016, 374(2):250-60

PubMed: 26921131 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27849011 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Biol Chem, 2016, 397(7):671-8

PubMed: 26910743 ( click the link to review the publication )

PLoS ONE, 2016,

PubMed: 26962861 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0162634

PubMed: 27611696 ( click the link to review the publication )
Thorac Cancer, 2016, 7(3):279-87

PubMed: 27148412 ( click the link to review the publication )

Cell Biochem Funct, 2016, 34(2):69-81

PubMed: 26919061 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65627-65642

PubMed: 27582537 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(34):54883-54896

PubMed: 27448972 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19214-27

PubMed: 27036037 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13886-901

PubMed: 26883104 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(32):9990-5

PubMed: 26216950 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )
EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1593

PubMed: 25590803 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

Cancer Sci, 2015,

PubMed: 25483727 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(5):1649-64

PubMed: 26175935 ( click the link to review the publication )

Gynecol Oncol, 2015, 139(1):118-26

PubMed: 26232337 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

BMC Cancer, 2015,

PubMed: 26205886 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26270481 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )
PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(32):32930-43

PubMed: 26431379 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25999352 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Sci Signal, 2014, 7(357):ra122

PubMed: 25538080 ( click the link to review the publication )

Sci Signal, 2014, 7(349):ra102

PubMed: 25351247 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )
Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

Am J Cancer Res, 2014,

PubMed: 25520871 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )
Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12862-76

PubMed: 25404640 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e827

PubMed: 24091670 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )
Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

J Biol Chem, 2013, 288(41):29821-35

PubMed: 23963458 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012,

PubMed: 22989520 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )
Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

靶点

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	点击更多
4 nM	5 nM	6 nM	7 nM	21 nM	点击更多

体外研究

BEZ235显著降低mTOR活化的激酶p70S6K的磷酸化水平。BEZ235导致S235/S236P-RPS6水平减少，IC50为6.5 nM。BEZ235抗mTOR的活性使用生化mTOR K-LISA试验测定，IC50为20.7 nM。BEZ235对其β旁系同源物的活性稍弱，IC50为75 nM。在人肿瘤细胞中，PI3K/Akt/mTOR通路经常被组成性活化。BEZ235阻断PI3K和mTOR激酶活性，通过结合于这些酶的ATP结合槽发挥作用。用逐渐增加浓度BEZ235处理PTEN-null细胞系PC3M和U87MG时，导致细胞增殖剂量依赖性减少，平均GI50为10-12 nM。^[1] BEZ235是一种mTORC1/2催化抑制剂。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	MkXNRY51cW2rY4LvZolidCCDc4PhfS=>		NXXB[nBzOThiaB?=	MmfaSG1UVw>?	MYDBcpRqfHK7cHHuc5NwdWGuIHHjeIl3cXS7IIfpeIghTUN3MDDv[kAxNjByMkWg{txO	NYLPcmJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NFU6PDZpPkK0PFA2QTR4PD;hQi=>
MCF7	NXTm[VdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzucItvOC5yMT2xNFAh\|ryP	NX:z[4wxPDhiaB?=	NILvPWtFVVOR	NWXpd\|NMUUN3ME2wMlc{KM7:TR?=	M4G0fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEexPVA1Lz5{M{i3NVkxPDxxYU6=
HCT116	MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfQUpVwOC5yMT2xNFAh\|ryP	NWm5bYZmPDhiaB?=	M1X6e2ROW09?	NWfSNVlRUUN3ME2xMlE3KM7:TR?=	MlfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{G5NFQoRjJ\|OEexPVA1RC:jPh?=
U87MG	NE\UTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHDcINSOC5yMT2xNFAh\|ryP	MUi0PEBp	MnTTSG1UVw>?	MXfJR\|UxRTFwM{Kg{txO	M37JWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEexPVA1Lz5{M{i3NVkxPDxxYU6=
HBC4	NETzO3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7uNE4xOS1zMECg{txO	NU\aSIc6PDhiaB?=		MnW1UI9oKEeLNUC9MVgvPjFiTR?=	MnnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
BSY1	NWDyToxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnnNE4xOS1zMECg{txO	MofLOFghcA>?		NXO5UYdGVG:pIFfJOVA:NThwNEigUS=>	NHvDS3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
HBC5	M3HhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPnXnoxNjBzLUGwNEDPxE1?	MV[0PEBp		MkHHUI9oKEeLNUC9MVcvQDdiTR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
MCF7	M2rreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;ZPIwxNjBzLUGwNEDPxE1?	NVr1[\|ZoPDhiaB?=		NYiy[ZQ4VG:pIFfJOVA:NThwMU[gUS=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
MDA-MB-231	M{LpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVWwMlAyNTFyMDFOwG0>	MmrnOFghcA>?		M1nmcGxw\yCJSUWwQU05NjB7IF2=	M1jOb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
U251	NWHmbG0zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rDTFAvODFvMUCwJO69VQ>?	NUi5d21RPDhiaB?=		MXrMc4chT0l3ME2tO{43PiCP	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SF268	NXHOVZBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PyS\|AvODFvMUCwJO69VQ>?	MlnyOFghcA>?		M2m0emxw\yCJSUWwQU04Njl{IF2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SF295	NVXIdYEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjhd4dwOC5yMT2xNFAh\|ryP	NED1UIs1QCCq		MkPEUI9oKEeLNUC9MVgvOzFiTR?=	NX;NVGN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
SF539	MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;RRZlKOC5yMT2xNFAh\|ryP	MYO0PEBp		MmHuUI9oKEeLNUC9MVgvPTliTR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SNB75	NYLzZXlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1m1c\|AvODFvMUCwJO69VQ>?	M1e0bFQ5KGh?		M1qzfGxw\yCJSUWwQU05NjV6IF2=	NIXUd5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
SNB78	NYKwXmFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrINE4xOS1zMECg{txO	M3z1bVQ5KGh?		MlvvUI9oKEeLNUC9MVgvPjViTR?=	NXjtU3k3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
HCC2998	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3reWRPOC5yMT2xNFAh\|ryP	NEnjdFc1QCCq		NFnvVJJNd2diR1m1NF0uQC5yNTDN	M{OwNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
KM12	NGj4cYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXwNE4xOS1zMECg{txO	MVy0PEBp		NUPKWWl5VG:pIFfJOVA:NTdwNUSgUS=>	M2fqblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
HT-29	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\4XVAvODFvMUCwJO69VQ>?	M17lfVQ5KGh?		M3:3VGxw\yCJSUWwQU04Njd3IF2=	NEG1c5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
HCT15	Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkD4NE4xOS1zMECg{txO	NFX3bJY1QCCq		MX3Mc4chT0l3ME2tPE4xOyCP	NIfSVW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
HCT116	M{XRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHnUYQxNjBzLUGwNEDPxE1?	NYXL[YFNPDhiaB?=		NVfYNmlYVG:pIFfJOVA:NTdwNkGgUS=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
NCI-H23	M{GybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2W0fVAvODFvMUCwJO69VQ>?	M4nYUFQ5KGh?		MXvMc4chT0l3ME2tO{43PCCP	MlPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
NCI-H226	NVfBZ4l2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnO2NE4xOS1zMECg{txO	NGLBPI01QCCq		NFnzRWFNd2diR1m1NF0uQC52NDDN	MlzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
NCI-H522	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGW2ZoUxNjBzLUGwNEDPxE1?	MlX0OFghcA>?		NGr1RlBNd2diR1m1NF0uQC52NTDN	MoDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
NCI-H438	NGO2Z2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjNPIdlOC5yMT2xNFAh\|ryP	MmO0OFghcA>?		M3rQdmxw\yCJSUWwQU05NjFzIF2=	NWDyWploRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
A549	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1O2RlAvODFvMUCwJO69VQ>?	M4LzSFQ5KGh?		MX\Mc4chT0l3ME2tPE4xPyCP	MoLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DMS273	M3u5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTzO2UxNjBzLUGwNEDPxE1?	M3HtflQ5KGh?		M2\WTGxw\yCJSUWwQU04NjhyIF2=	NV\PWmVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
DMS114	NG\VU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\rOY1ROC5yMT2xNFAh\|ryP	MoDUOFghcA>?		M2LoSmxw\yCJSUWwQU05NjN7IF2=	M{f5XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
LOXIMVI	MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUmwMlAyNTFyMDFOwG0>	M{W0UFQ5KGh?		MnvZUI9oKEeLNUC9MVgvPjZiTR?=	NYW4OlRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
OVCAR3	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlywNE4xOS1zMECg{txO	M3rVeVQ5KGh?		MVrMc4chT0l3ME2tPE4yPyCP	NFS2Z\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
OVCAR4	MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUmzPYxJOC5yMT2xNFAh\|ryP	MkLPOFghcA>?		MYDMc4chT0l3ME2tPE42QCCP	M3jpR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
OVCAR5	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXBNE4xOS1zMECg{txO	MY[0PEBp		M3KxTWxw\yCJSUWwQU04NjV5IF2=	NWXRWodiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
OVCAR8	NHP5VVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYmwMlAyNTFyMDFOwG0>	NVzCOIprPDhiaB?=		NYjQOYlKVG:pIFfJOVA:NTdwOESgUS=>	MoTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SKOV3	NH;QcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLWW21FOC5yMT2xNFAh\|ryP	NUXNTGoxPDhiaB?=		M4L4XGxw\yCJSUWwQU05NjRzIF2=	Mo\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
RXF631L	NUDKN5d1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XjdVAvODFvMUCwJO69VQ>?	M4TSUlQ5KGh?		M3HOTWxw\yCJSUWwQU05NjJzIF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
ACHN	NWXvOWJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknMNE4xOS1zMECg{txO	MknnOFghcA>?		NHzhbmZNd2diR1m1NF0uPy57NTDN	NWO5ZYY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
St-4	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\yRVAvODFvMUCwJO69VQ>?	MVS0PEBp		Mm\1UI9oKEeLNUC9MVcvPDdiTR?=	NHrlTIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
MKN1	NFLpbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fCXFAvODFvMUCwJO69VQ>?	NXThNVduPDhiaB?=		MW\Mc4chT0l3ME2tPE41OSCP	Mn7RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
MKN7	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTuVmsyOC5yMT2xNFAh\|ryP	MmC3OFghcA>?		M3f6W2xw\yCJSUWwQU04NjZ6IF2=	NHnjd5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
MKN28	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYizcGZ3OC5yMT2xNFAh\|ryP	NGPXUYQ1QCCq		NYfkeWljVG:pIFfJOVA:NTdwMEegUS=>	NF3ES\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
MKN45	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XGflAvODFvMUCwJO69VQ>?	MVy0PEBp		NH\nblRNd2diR1m1NF0uQC5\|NDDN	MnG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
MKN74	NGK2NVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWSwMlAyNTFyMDFOwG0>	NVvpelByPDhiaB?=		NYHHbWlrVG:pIFfJOVA:NTdwNEKgUS=>	M2i2SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
DU145	NGPZd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnuPY45OC5yMT2xNFAh\|ryP	NF[zbYY1QCCq		Mnf3UI9oKEeLNUC9MVgvOTZiTR?=	NV7DUZdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
PC3	NYXsenI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYewMlAyNTFyMDFOwG0>	M3nHelQ5KGh?		M336bmxw\yCJSUWwQU05NjZ4IF2=	NWDMRXRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
Trypanosoma brucei brucei	NUDYbHhlTnWwY4Tpc44hSXO\|YYm=	NVOwNINXOjByIH7N	MXGxNkBp	NF\BbXhFVVOR	M1vQbWRm[3KnYYPlJIlvKHCqb4PwbI91cWS7bDDpco9{cXSxbDDwbI9{eGijdHWgcIV3\Wx?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyNUm0Okc,OjR6MEW5OFY9N2F-
Trypanosoma brucei brucei	MmfsSpVv[3Srb36gRZN{[Xl?		NUnUe4R2OThiaB?=	MXPEUXNQ	MmWyTY5pcWKrdHnvckBw\iC{ZXPldJRwei2vZXTpZZRm\CCnbnTvZ5l1d3OrczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC2cnHud4ZmenKrbjD1dJRic2V?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyNUm0Okc,OjR6MEW5OFY9N2F-
Trypanosoma brucei brucei	MkHvSpVv[3Srb36gRZN{[Xl?	NXTqW\|AzOjByIH7N	MW[xNkBp	M{jXSmROW09?	MXfF[oZm[3Rib36gd5BpcW6pb335cIVqdiCuZY\lcC=>	M2\KNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEC1PVQ3Lz5{NEiwOVk1PjxxYU6=
Trypanosoma brucei brucei	M4LwRmZ2dmO2aX;uJGF{e2G7	MXKyNFAhdk1?	MmnzNVIhcA>?	NFfGUWJFVVOR	NXOzN\|BYTW[oZXP0JI9vKHCqb4PwbIF1cWS7bHPoc4xqdmVibHX2[Yw>	Mlv5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MEW5OFYoRjJ2OEC1PVQ3RC:jPh?=
UM-UC-3	NHnFWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfuZ4pQUUN3ME2zNVUheE1?	NGDsVXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SBC-1	NWq3VI9mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTd2MjDwUS=>	MmnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MKN1	NH71VXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULx[4Z7UUN3ME2yMlghdk1?	NUTyRm97RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H720	M3PocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7yNJdyUUN3ME2zMlU4KG6P	NVHi[JR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BFTC-909	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTNwN{Ggcm0>	NIHiRnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BPH-1	M2fvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPQc4o5UUN3ME20Mlc3KG6P	M1;nV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
PC-3	MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnxNoVKSzVyPUWuNFkhdk1?	MnnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
AN3-CA	M1;1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTVwNU[gcm0>	M{jU[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HN	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjXS2N3UUN3ME21Mlk3KG6P	NH;uSIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HCC2218	NVT6SGVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjITWM2OD14Lk[xJI5O	Mn;rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KP-4	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFm2UFNKSzVyPUegcm0>	NFjNfGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LU-139	NHnTdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3P3OWlEPTB;Nz63O{BvVQ>?	M{XWUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ETK-1	NF;lXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\ycGlEPTB;Nz64PEBvVQ>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3W2RWlEPTB;OD60PUBvVQ>?	M4qxZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MHH-PREB-1	NFvmcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTlwMUKgcm0>	NFi5SIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
DU-4475	NGTEeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoCwTWM2OD17LkS0JI5O	MnXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1666	NXjH[ZM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFuwZpNKSzVyPUmuO\|Ehdk1?	NGC0PZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAMA-1	M2Hpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTvPHFEUUN3ME25Mlghdk1?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
TYK-nu	MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPUd4VKSzVyPUmuPVQhdk1?	M37W[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MFE-280	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXzXG9EUUN3ME25Mlk6KG6P	M{fMeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A549	NF\EOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PSPGlEPTB;MUCuNVQhdk1?	Mnv2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
769-P	M4HuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLUTWM2OD1zMD60OEBvVQ>?	Mmq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
L-363	M1;yWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTFyLk[5JI5O	NH71dGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ES8	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfDTWM2OD1zMD65JI5O	M3HvSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
PA-1	M37Sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jSbmlEPTB;MUGuPFIhdk1?	NVztc4pIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
Mewo	NYDxPGJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjyPY5KSzVyPUGxMlk6KG6P	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HSC-3	NHW3fZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHh[I1SUUN3ME2xNk4zOSCwTR?=	NUHNT40zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
H4	Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmqwTWM2OD1zMj62O{BvVQ>?	NG\VPGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BB65-RCC	M4LKe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fLdWlEPTB;MUKuO\|Ihdk1?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1793	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7VVotxUUN3ME2xNk45OiCwTR?=	MkjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KARPAS-45	MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTF\|LkWxJI5O	M4\CeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
GCT	M3nSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXubohJUUN3ME2xN{43QCCwTR?=	NWGyVXdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EoL-1	M4rj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDKTWM2OD1zMz65N{BvVQ>?	NVTydWtERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LB2241-RCC	NFLEdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHzUWE6UUN3ME2xOE4xOSCwTR?=	Mn;IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
ES5	NEf3Vm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTF2Lke0JI5O	NYTVO2VYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LOXIMVI	NISwd\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTF2Lkm5JI5O	M{LoR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
COR-L105	MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzjTWM2OD1zNT6wOEBvVQ>?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
P12-ICHIKAWA	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTF3LkGgcm0>	M17KNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CHL-1	NY\pNJJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrnTWRtUUN3ME2xOU41PSCwTR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
VMRC-RCZ	MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7aTWM2OD1zNT62N{BvVQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HH	M1LUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\NTWM2OD1zNT63JI5O	M3zZWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NUGC-3	M{m2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHRTWM2OD1zNj6zOEBvVQ>?	NXjxfodqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EGI-1	M17DSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\UU\|dMUUN3ME2xOk41OyCwTR?=	M{ftcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
OS-RC-2	NVGwO\|BkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fkUGlEPTB;MU[uOFchdk1?	NF7sPZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MOLT-16	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vjZ2lEPTB;MUeuNVUhdk1?	MoTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H209	M160V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTF5LkK5JI5O	M1\hc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
697	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYT0eXVEUUN3ME2xO{41OyCwTR?=	Ml\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
D-56MG	NFPFUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3vZ5J[UUN3ME2xO{43QSCwTR?=	NU\VSVZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
VA-ES-BJ	NWXQXWVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrsc2lKSzVyPUG3Mlg{KG6P	NYfQSmJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EW-16	Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjMTWM2OD1zOD6wOEBvVQ>?	Mn3KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HGC-27	M3;IeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTF6LkC2JI5O	M1jHdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ES7	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTF6LkC5JI5O	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HuH-7	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NID2PXlKSzVyPUG4MlQhdk1?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BCPAP	NITTOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTF6Lk[1JI5O	Mlf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW1710	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXQ[XIxUUN3ME2xPE44OiCwTR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
IST-MEL1	NY\tXIQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTF6Lke3JI5O	NWH4U4c4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SF295	M37MPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfYTWM2OD1zOD65N{BvVQ>?	MkTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
RPMI-7951	NWH2WJQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIe2TIxKSzVyPUG5MlI5KG6P	NGHCbII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SF126	MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTF7LkSxJI5O	NVjWb\|hkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
GAMG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjxd2hKSzVyPUG5MlQ5KG6P	NGnzVlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KNS-81-FD	NXnJN3M2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHneGVKSzVyPUG5MlU1KG6P	NXK1cm9pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RT-112	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzoN3R[UUN3ME2xPU43PiCwTR?=	M1K1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
DEL	M4qxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvKVVZjUUN3ME2yNE41QSCwTR?=	NIHjUFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CGTH-W-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PXbmlEPTB;MkCuOlMhdk1?	NF[1SZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HOS	MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HvbmlEPTB;MkGuNFYhdk1?	NH3GcWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ES4	MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTJzLkC4JI5O	NIfj[Iw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RXF393	NVvsOXYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjNdlZJUUN3ME2yNU41PSCwTR?=	MoqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H2030	NHPFRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvaRWxZUUN3ME2yNU42OiCwTR?=	NXvWVnRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
YH-13	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3e4WGlEPTB;MkGuPFghdk1?	NWfOcJo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HT-1080	MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXSOZFSUUN3ME2yNU46OyCwTR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-SNU-1	NUT0dlhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fVe2lEPTB;MkGuPVUhdk1?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
G-402	NInsbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTrTWM2OD1{Mj6xOkBvVQ>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
786-0	MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPoTWM2OD1{Mj6yPUBvVQ>?	NV[xNIRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ME-180	NICyWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofYTWM2OD1{Mj60N{BvVQ>?	M{\jO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NB69	MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLz[5BUUUN3ME2yNk42OyCwTR?=	M4jxRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
J-RT3-T3-5	M4XnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrCcmVMUUN3ME2yNk46PiCwTR?=	M1;KTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TGBC1TKB	NXjDUYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTJ\|LkC1JI5O	MonZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW780	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvHNlVKSzVyPUKzMlE{KG6P	NX\NXlRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MG-63	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHmTWM2OD1{Mz60OUBvVQ>?	M2j0VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BV-173	Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MormTWM2OD1{Mz64O{BvVQ>?	NGjicWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAL-51	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLXXmQ4UUN3ME2yN{45QSCwTR?=	NH;STWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A375	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTJ\|LkmzJI5O	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MEL-HO	NGq3UVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPpUGtKSzVyPUK0MlA1KG6P	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EFO-27	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTJ2LkOzJI5O	M4CwcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
Hs-578-T	M2nF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1qzOmlEPTB;MkSuOVghdk1?	NGTnR5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NBsusSR	NGLLXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4npR2lEPTB;MkSuOkBvVQ>?	MoHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CTB-1	NYPSbodHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnBeo1KSzVyPUK0MlY4KG6P	M{LwdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
FTC-133	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PzRmlEPTB;MkWuNUBvVQ>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MOLT-4	MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHQb2VIUUN3ME2yOU4yOiCwTR?=	NW\qVGlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HO-1-N-1	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{n6SWlEPTB;MkWuNVUhdk1?	NW\IdIxURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ES3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXiwVpVlUUN3ME2yOU4zOiCwTR?=	M2O2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TI-73	MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXXUJJKSzVyPUK1MlI5KG6P	MlOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MPP-89	NHTpeGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1q1OmlEPTB;MkWuN\|Ihdk1?	MlO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KYSE-150	NWWxNZFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLlTJRiUUN3ME2yOU45QSCwTR?=	NHf5O4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LXF-289	MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXhdI5tUUN3ME2yOk4xPCCwTR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SK-LU-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTJ4LkG3JI5O	Mn;kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HOP-92	MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTJ4LkS4JI5O	Mn;CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HuO9	MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HaVWlEPTB;Mk[uO\|Yhdk1?	NX73SW1TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW962	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTiTWM2OD1{Nj63OkBvVQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RS4-11	NU[5dJdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjLSHZKSzVyPUK2MlkyKG6P	NETJWVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H292	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLjTWM2OD1{NzDuUS=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
DB	NILNOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2flUWlEPTB;MkeuN\|Yhdk1?	NYizbIVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW1088	M1r6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3wcWxtUUN3ME2yPE4zQSCwTR?=	M1rYUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A204	Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XRVWlEPTB;MkiuOFchdk1?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A3-KAW	NELhZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLiOldKSzVyPUK4MlY1KG6P	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MV-4-11	M1zMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnlb2xKSzVyPUK4Mlchdk1?	MmnKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
ES1	NH7rZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHS4TVhKSzVyPUK4Mlg1KG6P	NXmwfJd[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ONS-76	M1vmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGm0UFBKSzVyPUK5MlA2KG6P	M3HRbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
D-263MG	NIfHWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnEV4tKSzVyPUK5MlM2KG6P	NY\RWWlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
U-2-OS	MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3vTWM2OD1{OT61JI5O	MluyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
T98G	M1;sdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nPfmlEPTB;MkmuPFghdk1?	MmfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
GI-ME-N	NEjNTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfrblFVUUN3ME2yPU46OSCwTR?=	NXG5Z5hsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BHT-101	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn74TWM2OD1\|MD6wOUBvVQ>?	MkX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NOS-1	Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojBTWM2OD1\|MD6xNkBvVQ>?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
AsPC-1	NXLqPIx3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTNyLkKgcm0>	M3\o[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
QIMR-WIL	MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTNyLk[gcm0>	M{jCVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
JVM-3	Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDPcmxKSzVyPUOwMlg{KG6P	NGPnOnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KU-19-19	NX;2[ItyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGeyUJNKSzVyPUOxMlE{KG6P	Mkj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
OVCAR-8	M3fpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvQO5JKSzVyPUOxMlI3KG6P	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BEN	Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\jWmpqUUN3ME2zNU43OyCwTR?=	M{XYXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BE-13	Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnETWM2OD1\|MT64NkBvVQ>?	NXu3XZp6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EW-18	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HXe2lEPTB;M{GuPFYhdk1?	NXrseY9VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ECC10	M4Ds[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTNzLkm1JI5O	NI\UVoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CTV-1	NVLoUWpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHlUppbUUN3ME2zNk45OiCwTR?=	NGX4NHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
COLO-800	M{TMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjzTWM2OD1\|Mj65NkBvVQ>?	MkjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
A2058	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTN\|LkK1JI5O	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
VM-CUB-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37mUWlEPTB;M{OuOFMhdk1?	NVzLWG52RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
Ca9-22	M17MUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrDTWM2OD1\|Mz61OUBvVQ>?	Mn;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
COLO-684	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfWUY8{UUN3ME2zN{42QCCwTR?=	M4\kbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RPMI-8226	M1m3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfqTWM2OD1\|Mz64NkBvVQ>?	Mn;nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-NEP-1	M2\sUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDRTWM2OD1\|ND6xOUBvVQ>?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
Becker	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHP[G9pUUN3ME2zOE4zOSCwTR?=	NVjiWopzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H28	Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rvTGlEPTB;M{SuOFQhdk1?	M3qyWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CAL-120	NIey[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrmVWdKSzVyPUO0MlczKG6P	M4nISlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MDA-MB-157	NIXBNXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTN3LkSxJI5O	NFu5PXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
OVCAR-5	M4DQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTvSXpKSzVyPUO1MlQ4KG6P	NWrNbmEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LAMA-84	M{nFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLJeFVKSzVyPUO1Mlg4KG6P	MoP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAKI-1	MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjlfXNKSzVyPUO2MlQ{KG6P	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
Daoy	NG\W[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTN4Lkegcm0>	NI\m[Ik9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAL-62	M3vRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTN4Lki2JI5O	Mmr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
8-MG-BA	M3q2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTN5LkK1JI5O	NXz1So5jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
8505C	Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTN5LkWxJI5O	NF\UOWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LNCaP-Clone-FGC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTN5LkW5JI5O	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CAL-39	NFexZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnZRZdKSzVyPUO3Mlkhdk1?	M123bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MN-60	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTN5Lkm2JI5O	NE[xTXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RKO	Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnQXWhTUUN3ME2zPE4{OyCwTR?=	M1n0R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
U251	NH3nOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHPW4U4UUN3ME2zPE41OyCwTR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SJSA-1	NH7w[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTN6LkW0JI5O	NXvFdJlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CAL-12T	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknXTWM2OD1\|OD62JI5O	NIDzTHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HCC1419	NIjtVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\SS2lEPTB;M{iuO\|Ehdk1?	Mon2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CO-314	NVzBXIpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDBT\|N4UUN3ME2zPE44PCCwTR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	M3zzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHhTJRKSzVyPUO4MlgyKG6P	NETTU\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A101D	MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTKTWM2OD1\|OD65O{BvVQ>?	NGnlTpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MDA-MB-175-VII	M1PaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjCelBKSzVyPUO5MlUyKG6P	NXLQSnZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MZ2-MEL	NYLy[VZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\jNZpKSzVyPUO5MlY3KG6P	NUPmcYx4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NB5	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTRyLk[0JI5O	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
G-401	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTRyLkiyJI5O	MnqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HT	NVj1[JhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTRzLkCyJI5O	NFrn[YY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
8305C	NYrQb3RCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoP0TWM2OD12MT64O{BvVQ>?	M1LFVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BHY	NHTJR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fRSmlEPTB;NEKuO\|Ihdk1?	NUS0bog1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NTERA-S-cl-D1	NX3rTIxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4q0NWlEPTB;NEOgcm0>	NVT2[I51RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
T-24	NGWycWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTR\|LkizJI5O	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EPLC-272H	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTR2LkO5JI5O	NXfwZlVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
PSN1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTR2LkSgcm0>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H2452	NWHBOFFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DlR2lEPTB;NESuOVghdk1?	MmfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KS-1	NU\DT2VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTR2Lk[2JI5O	MnnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HD-MY-Z	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTuR5ZPUUN3ME20OE46OiCwTR?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KNS-62	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTR3LkO4JI5O	NEO5[mU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NOMO-1	M3\lXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLZTWM2OD12NT64O{BvVQ>?	MnjkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-HEP-1	M4fxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2GwUWlEPTB;NE[uNFQhdk1?	M{\PVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
IGR-1	NIThSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jCU2lEPTB;NE[uNVMhdk1?	M{LkWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KYSE-180	M4fsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTR4LkG3JI5O	MmixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EW-22	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPxTWM2OD12Nj6yJI5O	NHWxVHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1355	MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vPNWlEPTB;NE[uN\|Qhdk1?	NHzqcZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
DOHH-2	NWXPZo14T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLMNWRKSzVyPUS2MlM4KG6P	MlzYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
A4-Fuk	NVHGZ\|ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnERXJPUUN3ME20Ok42OiCwTR?=	MoXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
PC-14	MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTR4LkW3JI5O	NVLKOW82RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
TE-5	MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHJcGlKSzVyPUS2Mlg1KG6P	Mn;4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LB996-RCC	MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HFNGlEPTB;NEeuNVkhdk1?	Mn7mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1623	M2G3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zWNmlEPTB;NEeuO\|Yhdk1?	NH[2PXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1155	NFe3W5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLMSoxKSzVyPUS4MlMzKG6P	NGT5Z5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LoVo	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTR6LkSgcm0>	NF3KWpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MCF7	M2XjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlG5TWM2OD12OD61PEBvVQ>?	NWTaTHg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
AGS	M1nFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTR6Lke3JI5O	M1HnblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
PFSK-1	Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDsVFVKSzVyPUS5MlA3KG6P	Mlf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
22RV1	NVvhSmk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTR7LkC5JI5O	NUTYTWhwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
COR-L23	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTR7LkG2JI5O	NGTkVWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
D-283MED	NWG2bo1CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTpZ3dYUUN3ME20PU43OSCwTR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW982	NILlRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHSTWM2OD12OT65NUBvVQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW620	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7LW3JMUUN3ME21NE4{PiCwTR?=	Mo\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KYSE-140	M4fkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTVyLkW1JI5O	M2LSdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
GCIY	MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLOOINMUUN3ME21NE43PyCwTR?=	NV;lZWFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MHH-ESS-1	M1K1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTVzLkm1JI5O	MoXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
D-423MG	MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTV{LkC4JI5O	M{ntU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SF539	M2f0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTV{LkO1JI5O	M4nNT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RPMI-2650	NGK1PI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPoTWM2OD13Mj62PUBvVQ>?	NV7hd4FsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
GR-ST	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3Hm[GlEPTB;NUKuPFchdk1?	MkSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
YKG-1	NWHrVmx2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTV\|IH7N	NVXRO49nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SK-MES-1	MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTV\|LkK2JI5O	MnTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HLE	M{[wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TlcWlEPTB;NUOuOFchdk1?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RVH-421	MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXaRnlKSzVyPUWzMlY4KG6P	NH;1NmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
C32	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4r0cmlEPTB;NUOuPFMhdk1?	NEXmWIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
GB-1	NYriNWdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHZ[I1KSzVyPUW0MlIhdk1?	MnX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SNB75	NGfHWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPsbmhlUUN3ME21OE4zPiCwTR?=	NHX4PGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
EM-2	NVnjVpRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTV2LkSgcm0>	NEXXbWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RH-1	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWe4[HpKUUN3ME21OE44KG6P	M1i0elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NKM-1	M3rae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7yTWM2OD13ND64NUBvVQ>?	MkXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H2405	M3\Ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTV2Lki4JI5O	NFi2S249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KYSE-450	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXxTWM2OD13NT6xOkBvVQ>?	MoTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
A704	M{jaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH:5cG5KSzVyPUW1MlU6KG6P	MlvGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HAL-01	NVi4ZZJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTV3LkizJI5O	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
TE-11	NFfJXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnG1TWM2OD13NT65PUBvVQ>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
DOK	MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPqcpR6UUN3ME21Ok4xOiCwTR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KY821	NEjhcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jieWlEPTB;NU[uNkBvVQ>?	NXy3fmx4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KGN	NE[4Zm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTV4LkOyJI5O	NUP3OYhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MC116	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHG[ldbUUN3ME21O{45KG6P	NGi2VoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
PANC-08-13	NFXxeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTV6LkCxJI5O	M1fsSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KE-37	Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4j1XmlEPTB;NUiuO\|chdk1?	NX;VWpRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KYSE-410	MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;SNYJ3UUN3ME21PU41PyCwTR?=	NIi1ZY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RO82-W-1	NXfWSnhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTpZpFjUUN3ME21PU46KG6P	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
M14	NFiwbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTZyLkC0JI5O	NUXYdlBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
GI-1	M4i3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoS4TWM2OD14MD6zJI5O	NGPvZWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ML-2	MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDmZYp6UUN3ME22NE43OiCwTR?=	MoX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BFTC-905	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDvTWM2OD14MD62OUBvVQ>?	NELjSoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
DMS-273	NU[xc4tGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTZyLki3JI5O	NEW1Z3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MDA-MB-361	M2LXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7yVXVKSzVyPU[xJI5O	M4[zTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MSTO-211H	NUHLeZhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTZ\|LkWxJI5O	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MEG-01	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTZ\|LkWyJI5O	Mnm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
M059J	M3XEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1y2SmlEPTB;NkOuOVghdk1?	M2P6WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LN-405	M2\ZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTYbFhPUUN3ME22N{45PSCwTR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1581	MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7jZpVKSzVyPU[0MlA{KG6P	MkHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TCCSUP	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHmdW9KSzVyPU[0MlU{KG6P	MmDrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW872	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTZ2LkW3JI5O	MkXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KYSE-510	M3uxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTZ3Lke1JI5O	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1792	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnQZXRnUUN3ME22Ok4yPSCwTR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW13	M{fiT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTZ4LkWgcm0>	NIHVbY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
TE-8	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTZ4LkWyJI5O	M4H5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SCH	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHpTWM2OD14Nz6xJI5O	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NEC8	MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTZ5LkK0JI5O	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HuO-3N1	M2LYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XEVGlEPTB;NkeuN\|Ehdk1?	M1joNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
EFM-19	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zKU2lEPTB;NkeuOUBvVQ>?	NYjnT3ZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HEC-1	NXnTcIhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHSTWM2OD14Nz61NkBvVQ>?	M3LK[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
T47D	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlryTWM2OD14Nz64O{BvVQ>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SNU-423	M3fHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUn0cWRSUUN3ME22O{46QCCwTR?=	MoDkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
WM-115	Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TqcmlEPTB;NkiuNVQhdk1?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CaR-1	M4K3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rGV2lEPTB;NkiuNlUhdk1?	NW\GVFE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KU812	Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HHOmlEPTB;NkiuOlkhdk1?	MmXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
AM-38	NVP1clI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHmO2p4UUN3ME22PU4{OSCwTR?=	MkTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KOSC-2	Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rMZ2lEPTB;NkmuPVchdk1?	M1HDXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MC-IXC	M{nmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzyd29yUUN3ME23NE4xQCCwTR?=	NVfCS\|VwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SCC-4	M4rvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTdzLkO4JI5O	NI\XUJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
Calu-3	MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHJZlNKSzVyPUexMlk5KG6P	MnzmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
RPMI-8866	NFrWVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXJVYhKSzVyPUeyMlgzKG6P	MnTmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
OVCAR-4	M{L4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLDSGh6UUN3ME23N{4{PiCwTR?=	MljlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
OAW-42	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTd\|LkO5JI5O	M4[5[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ATN-1	M2Gwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4Xsd2lEPTB;N{OuPFchdk1?	M1fsb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CHP-212	MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfNN5VMUUN3ME23OE46PSCwTR?=	M2nzRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
C2BBe1	NH\KSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrpTWM2OD15NT6wN{BvVQ>?	M1r2elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A498	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjQR\|hKSzVyPUe1MlE2KG6P	NHTXUmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SH-4	NHrYR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfLd29PUUN3ME23OU4zOSCwTR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SNU-449	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4f6VWlEPTB;N{WuO\|khdk1?	NH7VPHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RD	MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPjS41jUUN3ME23OU45PiCwTR?=	M4nCflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
PANC-03-27	M4nLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHC[VdKSzVyPUe2MlI2KG6P	NIL4fZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
S-117	MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTd4LkK3JI5O	MojsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-MEL-2	NGnDcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTRVXUxUUN3ME23Ok44PSCwTR?=	M1;4UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LK-2	M1LNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7xUHFKSzVyPUe3MlA2KG6P	M{\6[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CP50-MEL-B	M2DCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTd5LkSgcm0>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
647-V	MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzZWVhUUUN3ME23PE4xPyCwTR?=	NXW5VXc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LU-134-A	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjuZZFbUUN3ME23PU4xOyCwTR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
5637	NInGVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoSwTWM2OD15OT6yN{BvVQ>?	M3fVbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1437	NEX4PXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITqO4pKSzVyPUiwMlUhdk1?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H460	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnYWlZ7UUN3ME24NU4zOyCwTR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BxPC-3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvaNG1KSzVyPUixMlQ3KG6P	M{nYeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CAN	NVuwZmg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2n2SGlEPTB;OEGuPFQhdk1?	NHjBdo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KINGS-1	NXLXTmc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHkS2dbUUN3ME24Nk4{OiCwTR?=	NIrtToU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
OCUB-M	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGSxTodKSzVyPUiyMlQyKG6P	M3nsbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KALS-1	NVezWVFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2m4T2lEPTB;OEKuOVQhdk1?	NWXlTopSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
OCI-AML2	NFS1NJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TSN2lEPTB;OEKuOlEhdk1?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A253	M1LRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHT3Z5NKSzVyPUiyMlY2KG6P	MnTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LCLC-97TM1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXObVJKSzVyPUiyMlg3KG6P	M2XoRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H520	M3Gwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2[zTWlEPTB;OEOuNFYhdk1?	NXjydlAzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
P30-OHK	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEX0c5ZKSzVyPUizMlUhdk1?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SBC-5	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPEbIQ1UUN3ME24N{42OiCwTR?=	M1nEOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HCE-T	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTh\|Lke0JI5O	MlvRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
JEG-3	NWnYNHdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnXRmpKSzVyPUi0MlEhdk1?	MkH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KG-1	NFK2V4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\ZdYVKSzVyPUi0MlI1KG6P	NHXxSXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MIA-PaCa-2	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXP0U4d6UUN3ME24OE42PCCwTR?=	MkLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAL-33	M1TUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXj0UJNNUUN3ME24OU4xQCCwTR?=	NYL0eI84RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
639-V	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELFWmpKSzVyPUi1MlQzKG6P	MoPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1048	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTh4LkOxJI5O	NXLTeZJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1573	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfBTWM2OD16Nz60PEBvVQ>?	NVzwXpBURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H2228	M4K0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nlNGlEPTB;OEiuNlYhdk1?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NB14	M3;Fdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrGW3IyUUN3ME24PE4{KG6P	MnSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SCC-25	M2rlcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3VVXFwUUN3ME24PU45OiCwTR?=	NUP0dG1JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
A431	NGW0Xm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjkWWZKSzVyPUi5Mlk4KG6P	NVn1VFB2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SN12C	NIHlXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfWd4x6UUN3ME25NE43OiCwTR?=	MlKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HuCCT1	MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHpcHZKSzVyPUmwMlc3KG6P	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LS-123	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTl{LkG4JI5O	NV70e4h4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CAL-85-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHLTWM2OD17Mj60PEBvVQ>?	NEmySGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ES6	NYKxZ4s{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIqxWFFKSzVyPUmyMlg{KG6P	M1y5W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H650	NFHzRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTySnFQUUN3ME25OE4xQSCwTR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H446	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGeyO4ZKSzVyPUm1MlEzKG6P	NHrwXXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
EW-13	M2\JSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTl3Lke1JI5O	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HSC-2	NXLYbYNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlX3TWM2OD17NT64PUBvVQ>?	Mke3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
U031	MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHK0enBKSzVyPUm2Mlc{KG6P	NGD5RVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
EW-11	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH32[pNKSzVyPUm2Mlg5KG6P	NI\2Nok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
GAK	NH7QTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTl6LkmzJI5O	NWPHcItuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SK-OV-3	Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLSdJFKSzVyPUGwNE4xPyCwTR?=	NHq3OFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
OMC-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTFyMD6xPEBvVQ>?	NIj4cFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
TK10	NGXDSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTFyMD6yNUBvVQ>?	M1PneVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
EKVX	M3\Lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHmTWM2OD1zMECuOkBvVQ>?	NEDMSXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
Detroit562	M1nz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrJTINKSzVyPUGwNk4yPyCwTR?=	NVzYbWFpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SF268	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTCeolKSzVyPUGwNk4{PCCwTR?=	NXzXd3RjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SNU-387	M1;CUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlr3TWM2OD1zMESuNVchdk1?	NXnhd\|UxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MDA-MB-231	NHfkUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DwdGlEPTB;MUC1MlA3KG6P	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1563	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvpTWM2OD1zMEWuNVghdk1?	NEjsb4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
D-502MG	NILqeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTFyNT63JI5O	NUD0Zm1YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
A2780	M17zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHQdVJKSzVyPUGwOk41PyCwTR?=	M1f5TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
IA-LM	NFHBdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGK2PHVKSzVyPUGwO{42OSCwTR?=	NXr5UGlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
D-392MG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTFyNz61OEBvVQ>?	MkTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MS-1	NVq0VmdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\2TWM2OD1zMEeuO\|Ehdk1?	NVqzXm9PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW1990	M3X3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfGTFRRUUN3ME2xNFgvPTRibl2=	Mm\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HEL	NF\LRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\KU286UUN3ME2xNFkvOjlibl2=	M4r1PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW1573	NGnVUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XPNmlEPTB;MUC5MlMyKG6P	Ml\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW1783	NIDaT\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHPS2lHUUN3ME2xNVAvOjJibl2=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
COLO-680N	NYLJcYZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknCTWM2OD1zMUCuO\|Yhdk1?	NVviOolTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-N87	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnpWoRKSzVyPUGxNU4xPCCwTR?=	NVTVWIR2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SK-MEL-28	NYfRcHhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfQTWM2OD1zMUGuOVUhdk1?	NF\INnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BT-20	NVz2OY57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXmcXJKSzVyPUGxNk4xOSCwTR?=	NX;wRVZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1648	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1WwR2lEPTB;MUGzJI5O	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
no-11	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkL0TWM2OD1zMUOuNlghdk1?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MOLT-13	M373PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvnTWM2OD1zMUOuOFQhdk1?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H2170	NUj3d5pYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2P5UmlEPTB;MUG0MlUyKG6P	M17RRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HTC-C3	NFfFRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTFzNj64OUBvVQ>?	NXTtWphGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LU-99A	MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\3eIJKSzVyPUGxO{4zOSCwTR?=	NYPKeVdmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HCC2998	NHnvfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LUe2lEPTB;MUG3MlkzKG6P	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NB13	NHnEbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWC4dYZOUUN3ME2xNVcvQTlibl2=	M3jZeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
GT3TKB	NIHvT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTFzOD6wPEBvVQ>?	M1vSRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BT-549	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvxTWM2OD1zMUiuPVUhdk1?	M4[zclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H747	NH7GfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nsWWlEPTB;MUG5MlM1KG6P	M4roSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
EW-1	NH\B[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYi3VpE{UUN3ME2xNlAvOiCwTR?=	NVnrOmlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LB831-BLC	NFzOUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\pTWM2OD1zMkCuOlMhdk1?	NFWyeXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NMC-G1	M4LkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDzO5ZKUUN3ME2xNlEvOTFibl2=	NUX1PJJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
COLO-679	M{PXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITiPWFKSzVyPUGyNk4yPSCwTR?=	NUT3Und5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HL-60	NEK3eXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{K0W2lEPTB;MUKzMlEhdk1?	NITwcFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MKN7	NULkR5ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXmTWM2OD1zMkOuPFMhdk1?	MmLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
RERF-LC-MS	NFf6TWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTF{ND6zNUBvVQ>?	M3rCN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
DMS-114	NIrIWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vzdGlEPTB;MUK1MlA6KG6P	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HuP-T4	NF;QOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTF{Nj65O{BvVQ>?	M1znSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HCC2157	M{jmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LwTWlEPTB;MUK3MlUhdk1?	Moi3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SKG-IIIa	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrWO2ZjUUN3ME2xNlgvQCCwTR?=	NUHaZXZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HCT-116	NFz3[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTF\|MD62OEBvVQ>?	NYDXdYM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BB30-HNC	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTF\|MD63PEBvVQ>?	Mn36QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KYSE-270	NY\lc5g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jwXGlEPTB;MUOwMlg5KG6P	M3zFd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MFM-223	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDBSndUUUN3ME2xN\|EvPTFibl2=	M2rFfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NH-12	M3\rN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVKxTIRWUUN3ME2xN\|IvQTlibl2=	M1jlSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
U-118-MG	M1Xwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjYXXNKSzVyPUGzN{43OiCwTR?=	NUnhV2F4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ESS-1	NH3s[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\3TWM2OD1zM{WuNVghdk1?	NXjwOpBsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
D-247MG	NVnrXoNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfDZ3lvUUN3ME2xN\|UvOjFibl2=	NVrVWJV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
IGROV-1	NV7iOm84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4r2ZmlEPTB;MUO1Mlc3KG6P	M2jtNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
C-33-A	MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnoVGdqUUN3ME2xN\|UvQTdibl2=	NWDyPVlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1693	NFnqOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInOVWpKSzVyPUGzOk4yOiCwTR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MLMA	NHu1XXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DlemlEPTB;MUO2MlU5KG6P	MoHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-N-AS	M1nSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPlTWM2OD1zM{euNVchdk1?	NHG3eJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1755	NH;6[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLUZVJ[UUN3ME2xN\|gvQDVibl2=	Mn:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CHP-134	MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDWTWM2OD1zM{muOVUhdk1?	MlrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LS-513	M2q1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlz6TWM2OD1zNECuPVEheE1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
TE-12	NV3SZWNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4W4WGlEPTB;MUSwMlk{KG6P	MmLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KNS-42	M4X1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PGdGlEPTB;MUS0MlMhdk1?	NGjofVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SJRH30	NIHrcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTF2ND60OEBvVQ>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1092	NYHzblhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Czc2lEPTB;MUS0MlUzKG6P	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
H-EMC-SS	M1LDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTF2Nj64NUBvVQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SK-MEL-3	NUnDb\|Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILre5lKSzVyPUG0O{42PSCwTR?=	MnPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-N-FI	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTJToVMUUN3ME2xOFcvPTlibl2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H2126	NU[yVHNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPoRVJKSzVyPUG0PE4yPSCwTR?=	NX;mdWs6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1299	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXoeI1KSzVyPUG1NE4zOiCwTR?=	NFe3SnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CFPAC-1	M1XnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWD3dXJvUUN3ME2xOVAvPjZibl2=	M3\oU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H661	NV\FXFNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfab5NDUUN3ME2xOVEvOjZibl2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KYSE-70	MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3WfGdKSzVyPUG1NU44QSCwTR?=	M4jEblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW900	NVy2fXZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTF3ND62OUBvVQ>?	M2PhflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
Ca-Ski	M4\ZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{CySWlEPTB;MUW2MlM6KG6P	MlzlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HPAF-II	MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPodllKSzVyPUG1Ok41PyCwTR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LB2518-MEL	M4jUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFX2bWtKSzVyPUG1O{4yKG6P	NGnq[HU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LC-2-ad

研究领域

产品类型